Dyadic International Secures Grant for Antibody Development

The latest announcement is out from Dyadic International ( (DYAI) ).

Dyadic International has secured a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effective monoclonal antibodies targeting RSV and malaria using its C1 protein production platform. This initiative aims to enhance global access to affordable treatments for these diseases, which heavily impact low-income countries. By leveraging the C1 platform’s efficiency, Dyadic seeks to reduce production costs and improve accessibility to crucial therapeutics, addressing significant health disparities.

See more insights into DYAI stock on TipRanks’ Stock Analysis page.